Mirum Pharmaceuticals, Inc.
MIRM
Ранг среди акций
#3220
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Цена акции
$85.31
Рыночная капитализация
$5.54B
Изменение (1 день)
3.73%
Изменение (1 год)
16.82%
Страна
US
Торговля Mirum Pharmaceuticals, Inc. (MIRM)
Категория
Healthcare
Коэффициент P/S для Mirum Pharmaceuticals, Inc. (MIRM)
Коэффициент P/S на October 2026 TTM: 8.40
Согласно последним финансовым отчетам и цене акций Mirum Pharmaceuticals, Inc., текущий коэффициент P/S (TTM) составляет 8.40. В конце 2023 он составлял 6.48.
История P/S для Mirum Pharmaceuticals, Inc. с 2018 по 2026
Коэффициент P/S в конце каждого года
| Год | P/S | Изменить |
|---|---|---|
| 2026 (TTM) | 8.40 | 44.09% |
| 2024 | 5.83 | -9.93% |
| 2023 | 6.48 | -24.37% |
| 2022 | 8.56 | -66.12% |
| 2021 | 25.27 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Коэффициент P/S для аналогичных компаний или конкурентов
| Компания | P/S | Разница P/S | Страна |
|---|---|---|---|
| 10.02 | 19.31% |
US
|
|
| 40.55 | 382.73% |
US
|
|
| 3.96 | -52.85% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 20.78% |
NL
|
